A quality management system (QMS) is an integrated framework through which organizations can systematically plan and achieve their quality objectives. While the International Conference on Harmonisation (ICH) Q10 provides clear guidance for QMS in the pharmaceutical manufacturing sector, there is no harmonized regulatory guidance describing a framework that provides an enterprise-wide view of achievement of clinical quality objectives, that is capable of being customized to fit an organization's unique circumstances, and that accommodates the variability inherent in clinical development. In the absence of such guidance, clinical QMS varies dramatically across industry, sometimes resulting in over-engineered, cumbersome systems that are not adaptable or fit-for-purpose. This paper will describe the ongoing activities of a TransCelerate initiative developing a conceptual framework for a Clinical QMS designed to provide a consistent, streamlined, and proactive quality approach across all stages of clinical research.
A quality management system (QMS) is an integrated framework through which organizations systematically define quality objectives linked to their broader strategic goals and develop and implement the foundations, organizational structure and processes required to achieve these objectives. QMSs are increasingly and successfully being used to control quality and improve performance in complex environments in industries ranging from aviation to information technology. A fundamental aspect of a successful QMS is shared responsibility for quality across the organization. 1 In the research and development (R&D) arena, a clinical-focused QMS should create value for an organization, its partners, and other key stakeholders, including patients, by driving a culture that recognizes the importance of quality in transcending the risks of clinical development and protecting research participants.
However, while there is well-established guidance for QMS in the pharmaceutical manufacturing sector to support consistent product quality, 2 no harmonized guidance describes a foundational quality management framework for drug, biologic, and vaccine clinical development, despite a need to consistently deliver quality data to an array of internal and external stakeholders while protecting research participants. In public forums, regulatory agency representatives have encouraged sponsors to implement ''clinical quality management systems'' or ''clinical quality systems,'' [3] [4] [5] but to date there is no formal, globally accepted guidance or regulation outlining regulatory expectations for a clinical QMS. Clinical QMS have been described variously as combinations of senior management development and visible support for quality and compliance standards, understanding customer requirements, maintaining policies and procedures, providing adequate training, implementing quality control and quality assurance, developing risk-based monitoring and auditing, conducting trend analysis, reviewing metrics, having a robust corrective and preventative action (CAPA) process, and ensuring continual process improvements.
Official recommendations related to clinical quality are fragmented across multiple health authority guidance documents and are generally focused on select aspects of quality at the clinical trial level (such as risk-based monitoring). 6, 7 No existing guidance describes a framework that provides an integrated, enterprise-wide view of clinical quality that is capable of being customized to fit an organization's unique circumstances, while accommodating for the variability inherent in clinical development. Such an integrated and flexible framework would proactively and strategically prevent and/or reduce risks to quality, increase efficiency in clinical development, and move products to the market more quickly, benefiting patients and consumers.
The absence of harmonized regulatory guidance describing a QMS appropriate for clinical development has led to differing interpretations across companies about what a QMS is; this, in turn, has caused disparate implementation and created inefficiencies that impede innovation, particularly when organizations adopt the Good Manufacturing Practices (GMP)-focused International Conference on Harmonisation (ICH) Q10 guidance without considering the unique aspects of clinical development. Moreover, applying a GMP-centric QMS may inadvertently institutionalize the outdated practice of treating every error equally, rather than, as advocated by US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), focusing on ''errors that matter'' most to decision-making. 8 The need for a clearly defined, clinical-focused QMS conceptual framework was also evident in the results of a series of structured interviews conducted by TransCelerate QMS Initiative members with 15 member companies regarding their existing clinical QMS. These interviews included both quality and clinical operations professionals. Regardless of where interviewees sat within an organization, their evaluation of the efficiency and effectiveness of their clinical QMS indicated clear opportunities for improvement. On a scale of 1 to 10, with 10 being best, the average score for clinical QMS effectiveness was 6.6 (range, 3-10) and the average for efficiency was 6.2 (range, 1-8). In particular, interviewees reported challenges in the following areas:
Creating and sustaining a robust quality culture with sustained and visible leadership engagement. Establishing a common understanding of quality management systems in language relevant to all organizational functions involved in clinical development.
Proactively addressing important risks. Developing crisp, streamlined procedural documents and internal training programs relevant to clinical staff. Focusing resources on and ensuring appropriate escalation of critical quality issues. Developing enterprise quality metrics that integrate outputs from disparate quality dashboards.
Of note, the TransCelerate member companies that gave their existing clinical QMS high marks reported success in these areas. These respondents also indicated that their organizations benefited from a strong and sustained culture of quality, clear quality objectives, strong governance driving quality throughout the enterprise, a sound framework for enterprise risk management, and an expectation of evaluation and continuous improvement.
To address these challenges, the TransCelerate QMS Initiative is developing a concept paper describing a proactive, flexible, and practical conceptual framework for clinical quality, in close alignment with global health authorities. This conceptual framework is intended to support organizations in holistically managing quality across the range of clinical activities they may conduct, from phase 1 trials through postmarketing studies. The framework will help enable consistent and efficient delivery of reliable data that may be used by an organization, its partners, regulators, clinicians, patients, and consumers to make informed decisions concerning medicinal products.
Based upon the experience in the manufacturing sector with the ICH Q10 guidance, a clearly defined clinical quality management framework, ideally in harmonized regulatory guidance, can give organizations the means to efficiently achieve their quality and organizational objectives, reduce recurring quality-related issues that undermine patient safety and data integrity and consume resources, and ultimately increase confidence in clinical research and its results. Such a conceptual framework will integrate individual trial-level quality and risk management activities to provide an organization's leadership with a holistic view of whether clinical quality objectives are being met and risks to subjects and to data quality are appropriately addressed across the enterprise. Finally, a conceptual framework will help promote a culture of quality and knowledge management, permitting an organization to capitalize on opportunities to enhance the efficient delivery of quality data.
Two core concepts underpin the development of the proposed conceptual framework. First, the framework must facilitate and encourage proactive approaches, for example, through identifying and preventing risks to quality prospectively. This mirrors the focus on ''risk-based thinking'' woven throughout recent Good Clinical Practice (GCP)-focused guidance from FDA and EMA 6, 7 as well as in the 2015 revision of the foundational International Organization for Standardization (ISO) quality management standard (ISO 9001). 9 Second, the proposed framework must be flexible so that it can be adapted to any organizational size, operating context, or research environment. This flexibility will also support organizations who desire to integrate a clinically focused QMS with other Good Practices (GxP)-related management systems.
With these concepts in mind, the TransCelerate QMS Initiative developed an initial concept paper outline describing the foundations and elements of a clinical QMS conceptual framework (see the Appendix) to facilitate dialogue with health authorities and other stakeholders in the clinical trial ecosystem. These foundations and elements include those reported in our research as key contributors to success in the clinical arena as well as those contributing to a sustained culture of quality and performance across a variety of industries. Figure 1 depicts the foundations for this clinical QMS conceptual framework. The first foundation is a clear understanding of both the internal and external context within which an organization operates so that the QMS can be appropriately tailored. For example, an organization relies on having a clear understanding of its customers' expectations for quality. Health authorities are an important customer for clinical development. An organization needs to know more than which regulations apply to them; the greater need is for the organization to understand how health authorities interpret and apply those regulations in different scenarios.
The next 2 foundations relate to culture. During interviews, member companies cited a culture of quality as an important contributor to QMS performance. This is consistent with results from a 2014 survey conducted by the American Society of Quality that found ''adopting a philosophy of quality and promoting a strong culture of quality is critical to an organization's success.'' 1 The clinical QMS conceptual framework reflects culture in 2 dimensions:
1. Leadership's commitment to quality and actions important to establishing and maintaining this culture, and 2. an organizational commitment to quality, where each individual takes ownership for quality in their role and is empowered to drive quality.
The final foundation, continual evaluation and improvement of the framework (as tailored and adopted by a particular company), ensures that the framework will be responsive to change and able to meet evolving customer requirements for clinical quality. Figure 2 depicts the elements of the proposed clinical QMS framework. These elements reflect areas that have been reported to contribute to success in the clinical arena. Seven elements (represented by horizontal bars) support integrating quality into clinical development; the others (vertical) provide ongoing monitoring of the achievement of quality objectives and the health of the QMS itself.
Although risk management is a specific element, the concept of proactive, risk-based decision making is captured throughout the document, consistent with the 2015 revision of the ISO 9001 standard. For example, the outline recommends under ''Partnering'' that parties collaborating in clinical development related activities jointly and prospectively assess and determine actions needed to manage the risks of partnered activities.
The outline (see the Appendix) described in this publication provides an overview of what is being developed in the detailed concept paper. Development of the concept paper will be informed by ongoing dialogue with key stakeholders, including relevant health authorities. TransCelerate's QMS Initiative is also addressing two elements of the conceptual framework where member companies reported distinct challenges in holistic implementation: issue management and clinical knowledge management. QMS Initiative members are developing guidance on these two topics and are considering similar guidance for other elements described in this conceptual framework. Ultimately, the concept paper and supporting guidance for each element should provide clinical trial sponsors with a common, practical, and flexible concept for a clinical-focused QMS and may encourage regulatory alignment on this important topic.
The Clinical Quality Conceptual Framework described by the paper will focus on the development of drugs, biologics, and vaccines from first-in-human trials through post-marketing clinical activities, including non-interventional trials. Pharmacovigilance activities, other than those related to requirements for safety data collection, review, and reporting in the context of clinical development activities, are out-of-scope. The Framework leverages device-related quality concepts, as applicable.
Guiding Principles:
The Clinical Quality Conceptual Framework described in this Concept Paper will: 
Key Definitions
Enterprise-wide: Applied across an organization, at every level and unit, providing a portfolio-wide view of clinical development activities. Knowledge Management: Strategies and processes designed to identify, capture, structure, value, leverage, and share an organization's intellectual assets to enhance its performance, based on two critical activities: (1) capture and documentation of individual explicit and tacit knowledge, and (2) Risk Attitude: An organization's approach to assess and eventually pursue, retain, take, or turn away from risk (ISO 73:2009). Quality: The degree to which a product or service meets customer requirements (modified ICH Q10). Quality Objective: A means of translating quality policy and strategies into measurable activities (ICH Q10). Figure A1 shows the foundational aspects and elements needed for a Clinical QMS. 3. Establish a mechanism for continual evaluation and improvement of the Clinical QMS Given that clinical development is dynamic, the organization should monitor the environment for changes that might necessitate modification of its Clinical QMS. The organization should seek opportunities to enhance effectiveness and/or efficiency of its Clinical QMS. This may be accomplished through ongoing monitoring of process effectiveness and efficiency, conducting periodic self-assessment or internal audits, and/or engaging in benchmarking. Any modifications to an organization's Clinical QMS or its individual elements should be supported by appropriate change management activities.
Foundations and Elements of a Clinical QMS Conceptual Framework

Foundations for Establishing and Maintaining a Clinical QMS
Elements of a Clinical QMS Conceptual Framework
The following elements should be prospectively developed to integrate quality into all clinical development activities.
a. Processes: The organization should identify the processes for which procedural documents (e.g., standard operating procedures) need to be developed. Procedural documentation should be created or modified only as necessary to address customer requirements and risks to quality objectives. For any new or revised procedural evaluate, and appropriately address risks to achieving its quality objectives. To accomplish this, the organization should prospectively establish a framework for managing risks across all of its clinical activities. This framework should provide the foundations (e.g., the organizational plans, processes, and commitment) for risk management. The framework and associated risk management processes should permit the organization to differentiate significant risks from those with minimal impact on quality, patient safety, and data reliability and to focus resources on the former. Risks identified at the individual trial level should be integrated to provide an enterprise-wide view of risks and prioritized controls.
The organization should conduct and periodically review risk assessments to accomplish the following: A clearly defined pathway should focus attention on issues that could undermine the goals of the organization and the quality objectives and/or materially impact patient safety or data integrity, while avoiding unnecessary escalation. f. Knowledge Management: The organization should encourage sharing and transfer of knowledge in real-time to promote consistency and to facilitate sustained success of the organization. The organization should prospectively plan for capturing, sharing and retaining institutional and tacit knowledge. The organization should develop a knowledge management process that allows for easy access and retrieval of knowledge across the enterprise. g. Documentation Supporting Achievement of Quality:
The level of documentation for any clinical development-related process should be commensurate with the risks of the activity and the significance of the activity to achieving quality objectives and meeting customer requirements. How, where, and for what period of time documentation will be retained should be established prospectively.
The following elements describe ongoing monitoring of the achievement of quality objectives and the performance of the quality management framework.
a. Measuring Quality: The organization should maintain ongoing surveillance of data, metrics, and other information across clinical activities and processes to proactively verify that quality objectives are consistently met and to identify any trends or issues requiring follow-up. This evaluation should be linked to the organization's risk assessment to determine whether proactively defined risk controls are effective and efficient and if new or emerging risks to quality merit attention. Care should be taken to ensure that metrics or any quality and risk indicators are meaningful measures of quality objective achievement. b. Management Review: Management with the accountability and appropriate decision making authority should periodically review its Clinical QMS to ensure that it remains fit for purpose, fulfills the quality objectives, and provides benefits that exceed the burden of maintenance. Based upon this review, management should determine the need for action and communicate decisions and any necessary actions to all appropriate levels within the organization.
